相关实验视频
Updated: Jun 25, 2026
10:33
Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
21.0K
双响应的磁脂体稳定皮克林乳液酸水凝珠用于口服药物输送
Chin Siew Sia1, Wen Ao Bong2, Bey-Hing Goh3
1Department of Chemical Engineering, School of Engineering, Monash University Malaysia, 47500 Subang Jaya, Selangor, Malaysia.
International journal of biological macromolecules
|July 30, 2025
概括
磁脂体 (MLPs) 稳定皮克林乳液被整合到双响应的水凝珠中. 这种新的系统提高了口服输送的稳定性,并允许控制地释放疏水性和疏水性化合物.
科学领域:
- 纳米技术纳米技术
- 材料科学 材料科学 材料科学
- 生物医学工程 生物医学工程
背景情况:
- 磁性脂体 (MLP) 是混合的纳米结构,在脂双层内结合了超超磁性氧化铁纳米粒子 (SPIONs).
- MLPs作为皮克林乳液的有效稳定剂,由于其两性质和嵌入式SPIONs,提供了硬质和磁性控制.
- 在胃肠道疾病中,MLP的结构不稳定性阻碍了它们的口服应用.
研究的目的:
- 开发一个强大的双响应水凝珠系统,以提高MLP稳定皮克林乳液的胃肠稳定性.
- 创建一个多功能平台,同时封装和刺激响应的交付的疏水性和疏水性化合物.
主要方法:
- 在生物聚合物基的水凝网络中集成交界活性MLP,以形成复合珠.
- 评估结构完整性,pH/磁性响应,以及在模拟胃肠道条件下的稳定性.
- 评估同时封装效率和抗过早泄漏的水性和水友性化合物.
主要成果:
- 复合水凝珠在模拟的胃肠道环境中显示出增强的结构完整性和稳定性.
- 该系统表现出对pH值和磁场的双重响应,使控制释放成为可能.
- 实现了对疏水性和疏水性化合物的同时封装,并抵御过早泄漏.
- 界面和物理化学分析证实了MLP在水凝基质中的稳定性和乳化功能.
结论:
- 稳定MLP的皮克林乳液水凝为口服输送系统提供了一个有希望的刺激响应平台.
- 开发的水凝珠系统克服了胃肠道中MLP结构不稳定的局限性.
- 这种方法促进了多种治疗剂的联合递送,提高了口服生物可用性和疗效.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...